Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.10 is 483% above its 3-year average of -0.02, near the high end of its 3-year range (-0.10–0.10).
As of the fiscal period ended Wednesday, December 31, 2025. 340.29% above its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 0.10.
DEBT TO EQUITY RATIO
0.10
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
-0.02
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+340.29%
CURRENT VS 3Y AVG
+483.47%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
-31.80%
vs the sector median at left
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.80M
Debt to Equity Ratio
0.10
TTM Avg
0.02
3Y Avg
-0.02
5Y Avg
N/A
Market Cap
$5.99M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.03
5Y Avg
0.04
Market Cap
$5.57M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$6.07M
Debt to Equity Ratio
0.05
TTM Avg
0.10
3Y Avg
0.21
5Y Avg
0.14
Market Cap
$5.37M
Debt to Equity Ratio
N/A
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$5.34M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.80M | 0.10 | 0.02 | -0.02 | N/A |
| Lucyd, Inc (LUCY)vs › | $5.86M | 0.01 | 0.00 | 0.01 | 0.28 |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.99M | 0.00 | 0.01 | 0.03 | 0.04 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.57M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | 0.05 | 0.10 | 0.21 | 0.14 |
| Femasys Inc. (FEMY)vs › | $6.13M | 1.19 | 2.02 | 1.11 | 0.84 |
| Biomerica, Inc. (BMRA)vs › | $6.27M | 0.72 | 0.51 | 0.31 | 0.26 |
| Lunai Bioworks Inc. (LNAI)vs › | $5.37M | N/A | 0.07 | 0.07 | 0.07 |
| Alzamend Neuro Inc (ALZN)vs › | $5.34M | 0.00 | 0.00 | 0.00 | 0.03 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.31M | 1.57 | 0.64 | 1.33 | 1.33 |
Debt/Equity
0.10
Current Ratio
2.35
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.10 |
| 2025-06-30 | 0.03 |
| 2024-12-31 | -0.06 |
| 2024-06-30 | -0.03 |
| 2023-12-31 | -0.04 |
| 2023-06-30 | -0.07 |
| 2022-12-31 | -0.10 |
